RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:17:00Z
Some May Be Optimistic About Stryker's (NYSE:SYK) Earnings
Wed 19 Feb 25, 12:22 PMSYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
Mon 17 Feb 25, 12:29 PMStryker launches ProCeed hospital bed
Mon 17 Feb 25, 12:07 AMWhy Stryker Corporation (SYK) is the Best Medical Device Stock to Buy
Wed 12 Feb 25, 02:14 PMStryker announces Allan Golston will retire from Board of Directors
Mon 10 Feb 25, 09:05 PMIs Stryker Corporation (SYK) the Best Automation Stock to Buy According to Hedge Funds?
Fri 07 Feb 25, 10:06 AMStryker declares an $0.84 per share quarterly dividend
Wed 05 Feb 25, 01:00 PMStryker's (NYSE:SYK) Soft Earnings Don't Show The Whole Picture
Wed 05 Feb 25, 12:19 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2683.00M | 2281.00M | 1954.00M | 2562.00M | 2356.00M |
| Minority interest | - | - | - | - | - |
| Net income | 2358.00M | 1994.00M | 1599.00M | 2083.00M | 3553.00M |
| Selling general administrative | 6035.00M | 5752.00M | 5361.00M | 5356.00M | 5099.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 11578.00M | 10968.00M | 9057.00M | 9696.00M | 8938.00M |
| Reconciled depreciation | 998.00M | 990.00M | 812.00M | 778.00M | 723.00M |
| Ebit | 2841.00M | 2584.00M | 2223.00M | 2713.00M | 2583.00M |
| Ebitda | 4241.00M | 3780.00M | 3069.00M | 3875.00M | 3306.00M |
| Depreciation and amortization | 1400.00M | 1196.00M | 846.00M | 1162.00M | 723.00M |
| Non operating income net other | -158.00000M | -303.00000M | -269.00000M | -151.00000M | -181.00000M |
| Operating income | 2841.00M | 2584.00M | 2223.00M | 2713.00M | 2537.00M |
| Other operating expenses | 15407.00M | 14421.00M | 12111.00M | 11979.00M | 11041.00M |
| Interest expense | 158.00M | 509.00M | 303.00M | 535.00M | 0.00000M |
| Tax provision | 325.00M | 287.00M | 355.00M | 479.00M | -1197.00000M |
| Interest income | 243.00M | 269.00M | 213.00M | 125.00M | 139.00M |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | 0.00000M | 1559.00M |
| Non recurring | 216.00M | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 325.00M | 287.00M | 355.00M | 479.00M | -1197.00000M |
| Total revenue | 18449.00M | 17108.00M | 14351.00M | 14884.00M | 13601.00M |
| Total operating expenses | 8536.00M | 8281.00M | 6817.00M | 6791.00M | 6378.00M |
| Cost of revenue | 6871.00M | 6140.00M | 5294.00M | 5188.00M | 4663.00M |
| Total other income expense net | -158.00000M | -303.00000M | -269.00000M | -151.00000M | -204.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 2358.00M | 1994.00M | 1599.00M | 2083.00M | 3553.00M |
| Net income applicable to common shares | 2358.00M | 1994.00M | 1599.00M | 2083.00M | 3553.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 36884.00M | 34631.00M | 34330.00M | 30167.00M | 27229.00M |
| Intangible assets | 4885.00M | 4840.00M | 5554.00M | 4227.00M | 4163.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 787.00M | 662.00M | 488.00M | 760.00M | 747.00M |
| Total liab | 20268.00M | 19754.00M | 21246.00M | 17360.00M | 15499.00M |
| Total stockholder equity | 16616.00M | 14877.00M | 13084.00M | 12807.00M | 11730.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3699.00M | 3413.00M | 3470.00M | 2866.00M | 2630.00M |
| Common stock | 38.00M | 38.00M | 38.00M | 37.00M | 37.00M |
| Capital stock | 38.00M | 38.00M | 38.00M | 37.00M | 37.00M |
| Retained earnings | 14765.00M | 13480.00M | 12462.00M | 11748.00M | 10765.00M |
| Other liab | 1751.00M | 2733.00M | 2975.00M | 2428.00M | 2206.00M |
| Good will | 14880.00M | 12918.00M | 12778.00M | 9069.00M | 8563.00M |
| Other assets | 3874.00M | 4023.00M | 3539.00M | 2560.00M | 2479.00M |
| Cash | 1844.00M | 2944.00M | 2943.00M | 4337.00M | 3616.00M |
| Cash and equivalents | 1844.00M | 2944.00M | 2943.00M | 4337.00M | 3616.00M |
| Total current liabilities | 6303.00M | 4549.00M | 5041.00M | 4400.00M | 4807.00M |
| Current deferred revenue | - | - | - | - | 158.00M |
| Net debt | 11204.00M | 9528.00M | 10287.00M | 5894.00M | 4870.00M |
| Short term debt | 1191.00M | 7.00M | 761.00M | 859.00M | 1373.00M |
| Short long term debt | 1191.00M | 7.00M | 761.00M | 859.00M | 1373.00M |
| Short long term debt total | 13048.00M | 12472.00M | 13230.00M | 10231.00M | 8486.00M |
| Other stockholder equity | 2034.00M | 1890.00M | 1741.00M | 1628.00M | 1559.00M |
| Property plant equipment | 2970.00M | 2833.00M | 2752.00M | 2567.00M | 2291.00M |
| Total current assets | 10275.00M | 10017.00M | 9707.00M | 11360.00M | 9733.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | -3149.00000M | -2881.00000M | -5248.00000M | -489.00000M | -996.00000M |
| Short term investments | 84.00M | 75.00M | 81.00M | 88.00M | 83.00M |
| Net receivables | 3565.00M | 3022.00M | 2701.00M | 2893.00M | 2332.00M |
| Long term debt | 11857.00M | 12472.00M | 13230.00M | 10231.00M | 8486.00M |
| Inventory | 3995.00M | 3314.00M | 3494.00M | 3282.00M | 2955.00M |
| Accounts payable | 1413.00M | 1129.00M | 810.00M | 675.00M | 646.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -221.00000M | -531.00000M | -1157.00000M | -606.00000M | -631.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 38.00M | 38.00M | 38.00M | 37.00M | 37.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 14765.00M | 13480.00M | 12462.00M | 11748.00M | 10765.00M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2464.00M | 2263.00M | 2009.00M | 1369.00M | 2479.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 26609.00M | 24614.00M | 24623.00M | 18807.00M | 17496.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 11857.00M | 12472.00M | 13230.00M | 10231.00M | 8486.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2924.00000M | -859.00000M | 7.00M | -5.00000M | 168.00M |
| Change to liabilities | 223.00M | 325.00M | 13.00M | -106.00000M | 159.00M |
| Total cashflows from investing activities | -2924.00000M | -859.00000M | -4701.00000M | -1455.00000M | -2857.00000M |
| Net borrowings | 472.00M | -1153.00000M | 989.00M | 1293.00M | 2456.00M |
| Total cash from financing activities | -749.00000M | -2365.00000M | -11.00000M | 3.00M | 1329.00M |
| Change to operating activities | 64.00M | 279.00M | 866.00M | -177.00000M | 243.00M |
| Net income | 2358.00M | 1994.00M | 1599.00M | 2083.00M | 3553.00M |
| Change in cash | -1100.00000M | 1.00M | -1394.00000M | 721.00M | 1074.00M |
| Begin period cash flow | 2944.00M | 2943.00M | 4337.00M | 3616.00M | 2542.00M |
| End period cash flow | 1844.00M | 2944.00M | 2943.00M | 4337.00M | 3616.00M |
| Total cash from operating activities | 2624.00M | 3263.00M | 3277.00M | 2191.00M | 2610.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 998.00M | 990.00M | 812.00M | 778.00M | 723.00M |
| Other cashflows from investing activities | -2336.00000M | 5.00M | -4221.00000M | -801.00000M | -2453.00000M |
| Dividends paid | 1051.00M | 950.00M | 863.00M | 778.00M | 703.00M |
| Change to inventory | -762.00000M | -189.00000M | 27.00M | -400.00000M | -385.00000M |
| Change to account receivables | -579.00000M | -377.00000M | 354.00M | -563.00000M | -60.00000M |
| Sale purchase of stock | - | 0.00000M | 0.00000M | -307.00000M | -300.00000M |
| Other cashflows from financing activities | 955.00M | -264.00000M | 3149.00M | -205.00000M | -124.00000M |
| Change to netincome | 454.00M | 464.00M | 453.00M | 320.00M | -1447.00000M |
| Capital expenditures | 588.00M | 525.00M | 487.00M | 649.00M | 572.00M |
| Change receivables | -579.00000M | -377.00000M | 354.00M | -563.00000M | -60.00000M |
| Cash flows other operating | -68.00000M | 56.00M | 19.00M | 79.00M | 67.00M |
| Exchange rate changes | - | - | - | -18.00000M | -8.00000M |
| Cash and cash equivalents changes | -1049.00000M | 39.00M | -1435.00000M | 721.00M | 1074.00M |
| Change in working capital | -732.00000M | 279.00M | 866.00M | -670.00000M | -1666.00000M |
| Stock based compensation | 168.00M | 171.00M | 142.00M | 127.00M | 119.00M |
| Other non cash items | -226.00000M | 66.00M | -190.00000M | -253.00000M | 1463.00M |
| Free cash flow | 2036.00M | 2738.00M | 2790.00M | 1542.00M | 2038.00M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SYK Stryker Corporation |
-2.235 0.58% | 386.29 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| ABT Abbott Laboratories |
0.72 0.54% | 132.85 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| MDT Medtronic PLC |
0.39 0.44% | 87.39 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
-0.57 0.54% | 105.10 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
| SEMHF Siemens Healthineers AG |
1.98 3.42% | 60.00 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
2825 Airview Boulevard, Kalamazoo, MI, United States, 49002
| Name | Title | Year Born |
|---|---|---|
| Mr. Kevin A. Lobo | Chairman, CEO & Pres | 1965 |
| Mr. Glenn S. Boehnlein | VP & CFO | 1962 |
| Mr. Timothy John Scannell | Exec. Advisor | 1965 |
| Mr. Viju S. Menon | Group Pres of Global Quality & Operations | 1968 |
| Mr. J. Andrew Pierce | Group Pres of MedSurg & Neurotechnology | 1974 |
| Mr. Spencer S. Stiles | Group Pres of Orthopaedics & Spine | 1977 |
| Mr. William E. Berry Jr. | VP & Chief Accounting Officer | 1966 |
| Mr. Robert C. Cohen | CTO and VP of Global R&D - Joint Replacement | NA |
| Mr. Alan Douville | VP, Chief Information Officer & Chief Information Security Officer | NA |
| Mr. Jason Beach | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...